|
ASCO Secures Major Funding and Data License Agreements for CancerLinQ™, a “Rapid Learning” System to Transform Cancer Care and Speed the Search for Cures
|
|
|
PALONOSETRON INFUSION BAG LAUNCHED IN JAPAN
|
|
|
Helsinn Group, Switzerland Announces Support of CancerLinQ™
A Rapid Learning System in Oncology Funded by the Conquer Cancer Foundation of the American Society of Clinical Oncology
|
|
|
RICCARDO BRAGLIA - BEST SWISS ENTREPRENEUR OF THE YEAR 2012
The winner of the 2012 Swiss Entrepreneur of the Year award is: Riccardo Braglia, CEO, Helsinn Group Industry/High-Tech/Life Sciences category
|
|
|
Helsinn Grants Specialised Therapeutics Australia (STA) Rights to Anamorelin, a First-in-Class Compound to Treat Cachexia-Anorexia Related to Non-Small Cell Lung Cancer (NSCLC)
Helsinn Healthcare SA and STA reinforce their Cancer Supportive Care Alliance in Australia and New Zealand with a Distribution and License Agreement for the innovative phase III ghrelin receptor agonist
|
|
|
CEO's Newsletter: Fine Chemicals in Helsinn: shaping quality services and building innovative pharmaceutucal active ingredients .... Chimica fine in Helsinn disegnando servizi di qualità e creando principi attivi innovativi ...
|
|
|
Oral Palonosetron Shows Safe and Effective Control of Nausea and Vomiting Induced by Multiple Cycles of Chemotherapy
New data presented at the 2012 meeting of the European Society of Medical Oncology (ESMO) in Vienna show antiemetic efficacy maintained across the chemotherapy cycles and a positive safety profile
|
|
|
HELSINN GROUP, SWITZERLAND ANNOUNCES A LICENSE AGREEMENT FOR NETUPITANT - PALONOSETRON FIXED DOSE COMBINATION WITH CJ CHEILJEDANG, SOUTH KOREA FOR KOREA
Helsinn Group announces that on September 18th it has signed a license agreement with CJ CheilJedang, Korea for Helsinn’s new product for potential use in the prevention of chemotherapy-induced nausea and vomiting (CINV).
|
|
|
HELSINN GRANTS TO DARA EXCLUSIVE U.S. COMMERCIAL RIGHTS TO GELCLAIR®, AN FDA-CLEARED ORAL GEL FOR THE TREATMENT OF ORAL MUCOSITIS
Gelclair® Strengthens DARA’s Growing Portfolio of In-licensed Oncology and Oncology Supportive Care Products
|
|
|
CEO's Newsletter: Licensing: the strength of our model of doing business, the professionalis of making it unique ... Licensing: la forza del nostro modello di fare business, la professionalità di renderlo unico ....
|
|
|
THORNE RESEARCH, INC. AND HELSINN HEALTHCARE SA, ANNOUNCE ONCOQOL (TM)
OncoQuol nutritional supplements and personal care products now available through oncologists and other medical professionals in USA and Canada
|
|
|
HELSINN PARTNERS WITH THE EUROPEAN SCHOOL OF ONCOLOGY (ESO)
Starting July 1st the Swiss Group has become Gold sponsor of the Sharing Progress in Cancer Care (SPCC) Programme
|
|
|
Helsinn and Zealand Pharma announce the advance of elsiglutide into Phase II for the prevention of chemotherapy-induced diarrhea in cancer patients
|
|